The University of Chicago Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Steven Chmura and Ralph R. Weichselbaum.
Steven Chmura
Connection Strength
7.761
Ralph R. Weichselbaum
  1. Retuning the Radio in Radiobiology. J Natl Cancer Inst. 2018 04 01; 110(4):325-326.
    View in: PubMed
    Score: 0.631
  2. Rhythmic radiotherapy beats down TGF-ß. Cell Cycle. 2017 08 03; 16(15):1391.
    View in: PubMed
    Score: 0.601
  3. Rhythmic radiotherapy beats down TGF-ß. Cell Cycle. 2017 Aug 03; 16(15):1391.
    View in: PubMed
    Score: 0.601
  4. Stereotactic radiotherapy for pulmonary metastases. Semin Thorac Cardiovasc Surg. 2013; 25(4):292-9.
    View in: PubMed
    Score: 0.471
  5. YTHDF1 loss in dendritic cells potentiates radiation-induced antitumor immunity via STING-dependent type I IFN production. J Clin Invest. 2024 Sep 26.
    View in: PubMed
    Score: 0.247
  6. Epitranscriptional regulation of TGF-ß pseudoreceptor BAMBI by m6A/YTHDF2 drives extrinsic radioresistance. J Clin Invest. 2023 12 15; 133(24).
    View in: PubMed
    Score: 0.234
  7. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023 07 10; 41(7):1294-1308.e8.
    View in: PubMed
    Score: 0.225
  8. The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat Rev Clin Oncol. 2022 09; 19(9):585-599.
    View in: PubMed
    Score: 0.212
  9. Evaluation of Initial Metastatic Tumor Location and Radiation Response to Determine Outcomes in Patients Who Received Combination Stereotactic Body Radiotherapy and Immunotherapy for NSCLC. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):e449.
    View in: PubMed
    Score: 0.202
  10. Prospects for viral-based strategies enhancing the anti-tumor effects of ionizing radiation. Semin Radiat Oncol. 2001 Oct; 11(4):338-45.
    View in: PubMed
    Score: 0.201
  11. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.
    View in: PubMed
    Score: 0.200
  12. Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation. J Exp Med. 2021 03 01; 218(3).
    View in: PubMed
    Score: 0.193
  13. Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med. 2021 02 24; 13(582).
    View in: PubMed
    Score: 0.193
  14. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
    View in: PubMed
    Score: 0.188
  15. Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):17-26.
    View in: PubMed
    Score: 0.187
  16. Coronavirus Disease 2019 Infection Prevention and Control Practices in Wuhan Radiation Therapy. Adv Radiat Oncol. 2020 Jul-Aug; 5(4):637-639.
    View in: PubMed
    Score: 0.183
  17. Down-regulation of ceramide production abrogates ionizing radiation-induced cytochrome c release and apoptosis. Mol Pharmacol. 2000 Apr; 57(4):792-6.
    View in: PubMed
    Score: 0.181
  18. In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo. Clin Cancer Res. 2000 Feb; 6(2):737-42.
    View in: PubMed
    Score: 0.179
  19. Tumor-reprogrammed resident T cells resist radiation to control tumors. Nat Commun. 2019 09 02; 10(1):3959.
    View in: PubMed
    Score: 0.174
  20. Integration of radiotherapy and immunotherapy for treatment of oligometastases. Lancet Oncol. 2019 08; 20(8):e434-e442.
    View in: PubMed
    Score: 0.173
  21. Strategies for enhancing viral-based gene therapy using ionizing radiation. Radiat Oncol Investig. 1999; 7(5):261-9.
    View in: PubMed
    Score: 0.166
  22. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
    View in: PubMed
    Score: 0.156
  23. Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation. Cancer Res. 1997 Oct 01; 57(19):4340-7.
    View in: PubMed
    Score: 0.152
  24. Loss of ceramide production confers resistance to radiation-induced apoptosis. Cancer Res. 1997 Apr 01; 57(7):1270-5.
    View in: PubMed
    Score: 0.147
  25. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016 07 15; 122(14):2242-50.
    View in: PubMed
    Score: 0.139
  26. Stereotactic body radiotherapy for oligometastatic breast cancer: a new standard of care, or a medical reversal in waiting? Expert Rev Anticancer Ther. 2016 Jun; 16(6):625-32.
    View in: PubMed
    Score: 0.138
  27. Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 2012; 7(12):e50141.
    View in: PubMed
    Score: 0.109
  28. MicroRNA expression characterizes oligometastasis(es). PLoS One. 2011; 6(12):e28650.
    View in: PubMed
    Score: 0.102
  29. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012 Jun 01; 118(11):2962-70.
    View in: PubMed
    Score: 0.101
  30. Predictors of competing mortality in early breast cancer. Cancer. 2010 Dec 01; 116(23):5365-73.
    View in: PubMed
    Score: 0.093
  31. Outcomes in black patients with early breast cancer treated with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2011 Feb 01; 79(2):392-9.
    View in: PubMed
    Score: 0.091
  32. Magnetic resonance imaging identifies multifocal and multicentric disease in breast cancer patients who are eligible for partial breast irradiation. Cancer. 2008 Nov 01; 113(9):2408-14.
    View in: PubMed
    Score: 0.082
  33. An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res. 2008 Aug 15; 14(16):5255-9.
    View in: PubMed
    Score: 0.081
  34. Enhancing radiotherapy with genetically engineered viruses. J Clin Oncol. 2007 Sep 10; 25(26):4090-5.
    View in: PubMed
    Score: 0.076
  35. Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites. Clin Cancer Res. 2024 May 01; 30(9):1945-1958.
    View in: PubMed
    Score: 0.060
  36. Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J Clin Invest. 2023 05 15; 133(10).
    View in: PubMed
    Score: 0.056
  37. Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022 12; 3(12):1498-1512.
    View in: PubMed
    Score: 0.054
  38. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
    View in: PubMed
    Score: 0.050
  39. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
    View in: PubMed
    Score: 0.049
  40. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. PLoS One. 2018; 13(4):e0195149.
    View in: PubMed
    Score: 0.040
  41. Radiogenetic therapy: on the interaction of viral therapy and ionizing radiation for improving local control of tumors. Semin Oncol. 1997 Dec; 24(6):633-8.
    View in: PubMed
    Score: 0.039
  42. Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):450-461.
    View in: PubMed
    Score: 0.036
  43. Protein kinase C inhibition induces apoptosis and ceramide production through activation of a neutral sphingomyelinase. Cancer Res. 1996 Jun 15; 56(12):2711-4.
    View in: PubMed
    Score: 0.035
  44. Cross-talk between ceramide and PKC activity in the control of apoptosis in WEHI-231. Adv Exp Med Biol. 1996; 406:39-55.
    View in: PubMed
    Score: 0.034
  45. An analysis of radiation necrosis of the central nervous system treated with bevacizumab. J Neurooncol. 2014 Apr; 117(2):321-7.
    View in: PubMed
    Score: 0.030
  46. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol. 2013 Jun 01; 190(11):5874-81.
    View in: PubMed
    Score: 0.028
  47. The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. Radiat Oncol. 2012 Dec 18; 7:216.
    View in: PubMed
    Score: 0.027
  48. Feasibility and toxicity of hypofractionated image guided radiation therapy for large volume limited metastatic disease. Pract Radiat Oncol. 2013 Oct-Dec; 3(4):316-22.
    View in: PubMed
    Score: 0.027
  49. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81.
    View in: PubMed
    Score: 0.026
  50. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 2012 Mar; 107(1):207-12.
    View in: PubMed
    Score: 0.025
  51. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol. 2006 May; 28(5):1141-51.
    View in: PubMed
    Score: 0.017
  52. gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr Cancer Drug Targets. 2006 May; 6(3):197-205.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.